Jumpmind Announces Strategic Investment from Lone View Capital
15.9.2025 13:00:00 EEST | Business Wire | Press release
Jumpmind, a leading provider of innovative retail technology solutions, announced today that Lone View Capital (“Lone View”), a growth-oriented private equity firm focused on technology and software investments, has made a strategic investment, acquiring a controlling stake in the company.
Founded in 2008, Jumpmind was recently recognized as a Leader in the Forrester Wave™ for Point of Service Solutions (Q4 2024). The company’s flagship product, Jumpmind Commerce, is a cloud-native, microservices-based point of service platform that enables retailers to unify digital and in-store experiences, streamline checkout, and deliver more personalized customer interactions. Trusted by leading retailers worldwide, the platform supports device independence, rapid deployment, and highly configurable customer journeys – empowering enterprises to adapt quickly in today’s dynamic retail landscape. Jumpmind was named POS Solution of the Year in the 2025 RetailTech Breakthrough Awards.
In addition to its retail commerce platform, Jumpmind offers SymmetricDS and Metl, enterprise-grade tools for real-time data integration and synchronization. Used across industries worldwide, they deliver the resilience needed to keep critical operations running without interruption.
“Jumpmind has established itself as a trusted partner to leading retailers across North America, Europe, and Asia, with a cloud, and hardware agnostic platform that offers a differentiated alternative to legacy systems,” said Doug Ceto, Partner at Lone View Capital. “We are excited to partner with Joe and the Jumpmind team to build on this momentum, expand their reach, and help them grow into the next leader in retail software.”
Following the investment, Jumpmind CEO Joe Corbin will remain in his role and continue guiding the company’s growth.
“Lone View brings deep expertise in software and technology, along with a strong track record of scaling businesses, and we are excited to partner with them,” said Joe Corbin, CEO of Jumpmind. “This investment positions us to accelerate our product roadmap, deepen customer relationships, and continue delivering innovative software that transforms the retail experience.”
ScaleView Partners served as exclusive financial advisor to Jumpmind. Harris Williams served as financial advisor to Lone View. Massumi + Consoli served as legal counsel to Lone View.
About Jumpmind
Jumpmind is a leading provider of innovative retail technology solutions. Our cloud-native, mobile point of service platform empowers retailers to streamline operations, enhance customer experiences, and achieve sustainable growth. With a future-proof architecture and a focus on delivering exceptional value to our clients, Jumpmind is committed to shaping the future of retail technology. Jumpmind powers inspired in-store experiences for a growing list of leading retailers, including American Eagle Outfitters, Build-A-Bear Workshop, DTLR, Petco, Reitmans Canada Ltd., Shoe Palace, The Paper Store, Landmark Group, and The Vitamin Shoppe. Learn more about Jumpmind at www.jumpmind.com.
About Lone View Capital
Lone View Capital is a growth-oriented private equity firm investing across the technology ecosystem. Its team comprises both investors and operators who leverage their deep domain expertise to help exceptional management teams build, transform, and grow market-leading businesses. The firm is based in Los Angeles, CA. For more information about Lone View’s investment strategy and model, visit https://loneviewcap.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250915303895/en/
Contacts
For Lone View Capital:
Parveen Singh, Edelman Smithfield
parveen.singh@edelmansmithfield.com
For Jumpmind:
Erin Lutz, Lutz Public Relations and Marketing
erin@lutzpr.com
949.293.1055
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom